John Houston on clinical data
From 102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston · · BreakingBiotech
“As of mid-December our estrogen receptor PROTAC looks as though it has a best‑in‑class profile — we see on average ~62% degradation with several patients showing 90%+ degradation and a clinical benefit rate we announced around 42% in a heavily pretreated population.”
On , John Houston, Former CEO at Arvinas, spoke about clinical data during 102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston on BreakingBiotech.
About John Houston
John Houston, former CEO of Arvinas, discussed the company's progress with its PROTAC protein degradation technology in a 2021 interview. He described how the technology differs from traditional therapies by hijacking the cell's ubiquitin ligase machinery to tag proteins for degradation, with the PROTAC molecule then released to perform multiple rounds. Houston noted that the company's estrogen receptor-targeting asset, ARV-471, showed a best-in-class profile as of mid-December 2021, with an average of 62% degradation and a clinical benefit rate of 42% in a heavily pretreated population. He also mentioned that Arvinas signed a co-development and co-commercialization agreement with Pfizer for ARV-471, which included an upfront payment of $650 million, an equity purchase of $350 million, and milestones of up to $1.4 billion. Houston stated that Arvinas was in a healthy financial position with approximately $1.6 billion in cash and investments, allowing the company to advance its prostate cancer program, ARV-110, independently. He said the company was not actively seeking a partner for that program but could consider one later. Houston also discussed a joint venture with Bayer to form Earth Bio, an agrichem company applying protein degradation technology to plant health. He outlined future plans, including targeting difficult proteins like KRAS and BCL-6 in oncology and exploring tau species in neuroscience, with a goal of nominating a clinical candidate roughly every year.